Go Pro

Cronos Group (CRON) Competitors

Cronos Group logo
$3.14 -0.02 (-0.63%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$3.14 +0.00 (+0.16%)
As of 09/11/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRON vs. ACB, CGC, OGI, SNDL, and TLRY

Should you buy Cronos Group stock or one of its competitors? Cronos Group's main competitors and comparable companies include Aurora Cannabis (ACB), Canopy Growth (CGC), Organigram Global (OGI), SNDL (SNDL), and Tilray Brands (TLRY). Companies are selected based on similarities in market, industry, and size.

How does Cronos Group compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Cronos Group has a net margin of 39.08% compared to Aurora Cannabis' net margin of -32.26%. Cronos Group's return on equity of 4.85% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-32.26% 4.37% 3.45%
Cronos Group 39.08%4.85%4.62%

In the previous week, Aurora Cannabis had 3 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Aurora Cannabis and 2 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.89 beat Aurora Cannabis' score of 0.49 indicating that Cronos Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cronos Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Cronos Group has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$247.82M0.98-$88.13M-$1.41N/A
Cronos Group$146.59M7.89-$9.45M$0.2015.70

Cronos Group has a consensus target price of $2.30, indicating a potential downside of 26.75%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Cronos Group
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

Aurora Cannabis has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 7.8% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cronos Group beats Aurora Cannabis on 12 of the 17 factors compared between the two stocks.

How does Cronos Group compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$293.63M1.42-$190.29M-$0.45N/A
Cronos Group$146.59M7.89-$9.45M$0.2015.70

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 0.4% of Canopy Growth shares are held by company insiders. Comparatively, 7.8% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cronos Group has a net margin of 39.08% compared to Canopy Growth's net margin of -65.33%. Cronos Group's return on equity of 4.85% beat Canopy Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Canopy Growth-65.33% -21.91% -14.34%
Cronos Group 39.08%4.85%4.62%

In the previous week, Canopy Growth had 4 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Canopy Growth and 2 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.89 beat Canopy Growth's score of 0.86 indicating that Cronos Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Canopy Growth
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Cronos Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 26.75%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Cronos Group
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

Canopy Growth has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Summary

Cronos Group beats Canopy Growth on 13 of the 15 factors compared between the two stocks.

How does Cronos Group compare to Organigram Global?

Cronos Group (NASDAQ:CRON) and Organigram Global (NASDAQ:OGI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Cronos Group currently has a consensus price target of $2.30, indicating a potential downside of 26.75%. Given Cronos Group's stronger consensus rating and higher probable upside, research analysts clearly believe Cronos Group is more favorable than Organigram Global.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Cronos Group had 1 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for Cronos Group and 1 mentions for Organigram Global. Cronos Group's average media sentiment score of 1.89 beat Organigram Global's score of 1.87 indicating that Cronos Group is being referred to more favorably in the media.

Company Overall Sentiment
Cronos Group Very Positive
Organigram Global Very Positive

Cronos Group has higher earnings, but lower revenue than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$146.59M7.89-$9.45M$0.2015.70
Organigram Global$185.07M0.80-$17.70M$0.462.28

Cronos Group has a net margin of 39.08% compared to Organigram Global's net margin of 28.14%. Cronos Group's return on equity of 4.85% beat Organigram Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group39.08% 4.85% 4.62%
Organigram Global 28.14%-13.39%-8.67%

Cronos Group has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cronos Group beats Organigram Global on 11 of the 15 factors compared between the two stocks.

How does Cronos Group compare to SNDL?

SNDL (NASDAQ:SNDL) and Cronos Group (NASDAQ:CRON) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, SNDL had 2 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for SNDL and 2 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.89 beat SNDL's score of 0.97 indicating that Cronos Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SNDL
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cronos Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Cronos Group has a net margin of 39.08% compared to SNDL's net margin of -2.36%. Cronos Group's return on equity of 4.85% beat SNDL's return on equity.

Company Net Margins Return on Equity Return on Assets
SNDL-2.36% -2.01% -1.67%
Cronos Group 39.08%4.85%4.62%

Cronos Group has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SNDL$928.39M0.37-$11.29M-$0.06N/A
Cronos Group$146.59M7.89-$9.45M$0.2015.70

Cronos Group has a consensus price target of $2.30, indicating a potential downside of 26.75%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than SNDL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SNDL
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Cronos Group
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

SNDL has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

8.7% of Cronos Group shares are held by institutional investors. 7.8% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cronos Group beats SNDL on 13 of the 16 factors compared between the two stocks.

How does Cronos Group compare to Tilray Brands?

Cronos Group (NASDAQ:CRON) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Cronos Group has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$146.59M7.89-$9.45M$0.2015.70
Tilray Brands$915.45M0.60-$121.40M-$1.08N/A

In the previous week, Tilray Brands had 12 more articles in the media than Cronos Group. MarketBeat recorded 14 mentions for Tilray Brands and 2 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.89 beat Tilray Brands' score of 0.67 indicating that Cronos Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cronos Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Tilray Brands
5 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cronos Group has a net margin of 39.08% compared to Tilray Brands' net margin of -13.11%. Cronos Group's return on equity of 4.85% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group39.08% 4.85% 4.62%
Tilray Brands -13.11%-7.76%-5.59%

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 0.8% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cronos Group presently has a consensus target price of $2.30, suggesting a potential downside of 26.75%. Tilray Brands has a consensus target price of $8.00, suggesting a potential upside of 99.00%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts plainly believe Tilray Brands is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Tilray Brands
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.43

Cronos Group has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Summary

Cronos Group beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

Get Cronos Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRON vs. The Competition

MetricCronos GroupPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.16B$12.43B$7.16B$12.71B
Dividend YieldN/A2.62%2.56%11.16%
P/E Ratio15.70797.20272.9825.27
Price / Sales7.89758.78654.9999.48
Price / Cash252.0689.2577.0451.44
Price / Book1.0510.3910.336.20
Net Income-$9.45M$2.83B$3.49B$358.27M
7 Day Performance-3.68%-3.66%-3.33%-2.36%
1 Month Performance-0.95%0.82%-0.42%-2.77%
1 Year Performance24.11%3.50%19.22%7.64%

Cronos Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
1.6735 of 5 stars
$3.14
-0.6%
$2.30
-26.8%
+21.7%$1.16B$146.59M15.70450
ACB
Aurora Cannabis
1.2008 of 5 stars
$3.95
flat
N/A-24.1%$256.12M$247.82MN/A1,028
CGC
Canopy Growth
0.9267 of 5 stars
$0.97
flat
N/A-33.3%$437.03M$251.01MN/A1,128
OGI
Organigram Global
1.7643 of 5 stars
$1.16
flat
N/A-36.7%$162.86M$185.07M2.511,139
SNDL
SNDL
1.5866 of 5 stars
$1.44
flat
N/A-43.9%$369.36M$677.32MN/A2,751

Related Companies and Tools


This page (NASDAQ:CRON) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners